Tags : Advanced Renal Cell Carcinoma


Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced

Shots: The submission is based on METEOR, CABOSUN and Takeda’s bridging study. METEOR & CABOSUN studies result assessing Cabometyx vs everolimus & sunitinib in patients with RCC + prior treated with at least one VEGFR-TKI inhibitor & untreated advanced RCC with intermediate/poor-risk disease respectively In Q2’19, Exelixis is expected to receive $10M as milestones from […]Read More